Italy · Delayed Price · Currency is EUR Pharmanutra Statistics
Total Valuation
Pharmanutra has a market cap or net worth of EUR 826.34 million. The enterprise value is 816.43 million.
| Market Cap | 826.34M |
| Enterprise Value | 816.43M |
Important Dates
The next estimated earnings date is Thursday, May 28, 2026.
| Earnings Date | May 28, 2026 |
| Ex-Dividend Date | May 4, 2026 |
Share Statistics
Pharmanutra has 9.58 million shares outstanding. The number of shares has decreased by -0.60% in one year.
| Current Share Class | 9.58M |
| Shares Outstanding | 9.58M |
| Shares Change (YoY) | -0.60% |
| Shares Change (QoQ) | +0.37% |
| Owned by Insiders (%) | 65.81% |
| Owned by Institutions (%) | 11.71% |
| Float | 3.27M |
Valuation Ratios
The trailing PE ratio is 39.21 and the forward PE ratio is 33.48.
| PE Ratio | 39.21 |
| Forward PE | 33.48 |
| PS Ratio | 5.96 |
| PB Ratio | 11.10 |
| P/TBV Ratio | 16.59 |
| P/FCF Ratio | 51.42 |
| P/OCF Ratio | 42.49 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 24.32, with an EV/FCF ratio of 50.81.
| EV / Earnings | 38.84 |
| EV / Sales | 5.89 |
| EV / EBITDA | 24.32 |
| EV / EBIT | 26.96 |
| EV / FCF | 50.81 |
Financial Position
The company has a current ratio of 2.38, with a Debt / Equity ratio of 0.26.
| Current Ratio | 2.38 |
| Quick Ratio | 2.11 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | 0.57 |
| Debt / FCF | 1.19 |
| Interest Coverage | 40.22 |
Financial Efficiency
Return on equity (ROE) is 30.15% and return on invested capital (ROIC) is 32.14%.
| Return on Equity (ROE) | 30.15% |
| Return on Assets (ROA) | 15.05% |
| Return on Invested Capital (ROIC) | 32.14% |
| Return on Capital Employed (ROCE) | 31.31% |
| Weighted Average Cost of Capital (WACC) | 4.77% |
| Revenue Per Employee | 1.08M |
| Profits Per Employee | 164,234 |
| Employee Count | 128 |
| Asset Turnover | 1.10 |
| Inventory Turnover | 8.03 |
Taxes
In the past 12 months, Pharmanutra has paid 10.45 million in taxes.
| Income Tax | 10.45M |
| Effective Tax Rate | 33.30% |
Stock Price Statistics
The stock price has increased by +75.00% in the last 52 weeks. The beta is 0.10, so Pharmanutra's price volatility has been lower than the market average.
| Beta (5Y) | 0.10 |
| 52-Week Price Change | +75.00% |
| 50-Day Moving Average | 80.46 |
| 200-Day Moving Average | 60.35 |
| Relative Strength Index (RSI) | 65.17 |
| Average Volume (20 Days) | 14,825 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharmanutra had revenue of EUR 138.73 million and earned 21.02 million in profits. Earnings per share was 2.20.
| Revenue | 138.73M |
| Gross Profit | 70.76M |
| Operating Income | 30.29M |
| Pretax Income | 31.40M |
| Net Income | 21.02M |
| EBITDA | 33.09M |
| EBIT | 30.29M |
| Earnings Per Share (EPS) | 2.20 |
Balance Sheet
The company has 29.00 million in cash and 19.10 million in debt, with a net cash position of 9.91 million or 1.03 per share.
| Cash & Cash Equivalents | 29.00M |
| Total Debt | 19.10M |
| Net Cash | 9.91M |
| Net Cash Per Share | 1.03 |
| Equity (Book Value) | 74.47M |
| Book Value Per Share | 7.76 |
| Working Capital | 43.28M |
Cash Flow
In the last 12 months, operating cash flow was 19.45 million and capital expenditures -3.38 million, giving a free cash flow of 16.07 million.
| Operating Cash Flow | 19.45M |
| Capital Expenditures | -3.38M |
| Depreciation & Amortization | 2.81M |
| Net Borrowing | -4.96M |
| Free Cash Flow | 16.07M |
| FCF Per Share | 1.68 |
Margins
Gross margin is 51.01%, with operating and profit margins of 21.83% and 15.15%.
| Gross Margin | 51.01% |
| Operating Margin | 21.83% |
| Pretax Margin | 22.63% |
| Profit Margin | 15.15% |
| EBITDA Margin | 23.85% |
| EBIT Margin | 21.83% |
| FCF Margin | 11.58% |
Dividends & Yields
This stock pays an annual dividend of 1.20, which amounts to a dividend yield of 1.41%.
| Dividend Per Share | 1.20 |
| Dividend Yield | 1.41% |
| Dividend Growth (YoY) | 20.00% |
| Years of Dividend Growth | 5 |
| Payout Ratio | 45.62% |
| Buyback Yield | 0.60% |
| Shareholder Yield | 2.01% |
| Earnings Yield | 2.54% |
| FCF Yield | 1.94% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Pharmanutra is 94.33, which is 5.52% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 94.33 |
| Price Target Difference | 5.52% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |